Molcure
Tokyo
About Molcure
Molcure is antibody and Peptide drug-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of patients by developing and providing more effective therapeutics and supportive care products. Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure they combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies. Their technology is validated through a number of partnerships. They are seeking new partnership opportunities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2021)
- Website: molcure.comjp
- Phone: +81 44 400 1894
Industries & Categories
Artificial Intelligence (AI), Biopharma, Biotechnology, Machine Learning, Medical
Social Profiles
Canonical: https://fsome.com/organization/molcure-9907 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.